Oncotarget

Research Papers:

Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion

Xiaohui Si, Xiaoyun Zhang, Xing Hao, Yunan Li, Zizhen Chen, Yahui Ding, Hui Shi, Jie Bai, Yingdai Gao, Tao Cheng, Feng-Chun Yang and Yuan Zhou _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:78095-78109. https://doi.org/10.18632/oncotarget.12947

Metrics: PDF 861 views  |   HTML 950 views  |   ?  


Abstract

Xiaohui Si1, Xiaoyun Zhang1, Xing Hao1, Yunan Li1, Zizhen Chen1, Yahui Ding1, Hui Shi1, Jie Bai1, Yingdai Gao1,2,3, Tao Cheng1,2,3,4, Feng-Chun Yang5,6, Yuan Zhou1,2,3

1State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

2Center for Stem Cell Medicine, Chinese Academy of Medical Sciences, Tianjin, China

3Department of Stem Cell & Regenerative Medicine, Peking Union Medical College, Tianjin, China

4Collaborative Innovation Center for Cancer Medicine, Tianjin, China

5Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

6Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA

Correspondence to:

Yuan Zhou, email: yuanzhou@ihcams.ac.cn

Feng-Chun Yang, email: fxy37@med.miami.edu

Keywords: leukemia stem cell, microRNA, acute myeloid leukemia, miR-99a

Received: July 29, 2016    Accepted: October 14, 2016    Published: October 27, 2016

ABSTRACT

Leukemia stem cells (LSCs) can resist available treatments that results in disease progression and/or relapse. To dissect the microRNA (miRNA) expression signature of relapse in acute myeloid leukemia (AML), miRNA array analysis was performed using enriched LSCs from paired bone marrow samples of an AML patient at different disease stages. We identified that miR-99a was significantly upregulated in the LSCs obtained at relapse compared to the LSCs collected at the time of initial diagnosis. We also found that miR-99a was upregulated in LSCs compared to non-LSCs in a larger cohort of AML patients, and higher expression levels of miR-99a were significantly correlated with worse overall survival and event-free survival in these AML patients. Ectopic expression of miR-99a led to increased colony forming ability and expansion in myeloid leukemia cells after exposure to chemotherapeutic drugs in vitro and in vivo, partially due to overcoming of chemotherapeutic agent-mediated cell cycle arrest. Gene profiling and bioinformatic analyses indicated that ectopic expression of miR-99a significantly upregulated genes that are critical for LSC maintenance, cell cycle, and downstream targets of E2F and MYC. This study suggests that miR-99a has a novel role and potential use as a biomarker in myeloid leukemia progression.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12947